Vascular endothelial growth factor 2

Abstract

Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided are methods of using the antibodies and antagonists to inhibit the action of VEGF2 for therapeutic purposes.

What is claimed is:  
     
         1 . An isolated polynucleotide encoding for VEGF2, said polynucleotide selected from the group consisting of 
 (a) a polynucleotide encoding for the VEGF2 polypeptide having the deduced amino acid sequence of FIG. 1 or an active fragment, analogue or derivative of said polypeptide;    (b) a polynucleotide encoding for the VEGF2 polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75698 or an active fragment, analogue or derivative of said polypeptide.    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  wherein said polynucleotide encodes for VEGF2 having the deduced amino acid sequence of FIG. 1.  
     
     
         6 . The polynucleotide of  claim 2  wherein said polynucleotide encodes for the VEGF2 polypeptide encoded by the cDNA of ATCC Deposit No. 75698.  
     
     
         7 . The polynucleotide of  claim 1  having the coding sequence for VEGF2 as shown in FIG. 1.  
     
     
         8 . The polynucleotide of  claim 2  having the coding sequence for VEGF2 deposited as ATCC Deposit No. 75698.  
     
     
         9 . A vector containing the DNA of  claim 2 .  
     
     
         10 . A host cell genetically engineered with the vector of  claim 9 .  
     
     
         11 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 10  the polypeptide encodedby said DNA.  
     
     
         12 . A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of  claim 9 .  
     
     
         13 . An isolated DNA hybridizable to the DNA of  claim 2  and encoding a polypeptide having VEGF2 activity.  
     
     
         14 . A polypeptide selected from the group consisting of 
 (i) a VEGF2 polypeptide having the deduced amino acid sequence of FIG. 1 and active fragments, analogs and derivatives thereof; and    (ii) a VEGF2 polypeptide encoded by the cDNA of ATCC Deposit No. 75698 and active fragments, analogs and derivatives of said polypeptide.    
     
     
         15 . The polypeptide of  claim 14  wherein the polypeptide is VEGF2 having the deduced amino acid sequence of FIG. 1.  
     
     
         16 . An antibody against the polypeptide of  claim 14 .  
     
     
         17 . An antagonist against the polypeptide of  claim 14 .  
     
     
         18 . A method for the treatment of a patient having need of VEGF2 comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 14 .  
     
     
         19 . A method for the treatment of a patient having need to inhibit VEGF2 comprising: administering to the patient a therapeutically effective amount of an antagonist against the polypeptide of  claim 14 .  
     
     
         20 . A pharmaceutical composition comprising the polypeptide of  claim 14  and a pharmaceutically acceptable carrier.